Bibliographic Info
Recommendation
Recommended in favor
Conditional
Certainty of evidence
Very low
In multidrug-resistant TB or isoniazid-resistant, rifampicin-resistant TB patients on longer regimens, all three Group A agents and at least one Group B agent should be included to ensure that treatment starts with at least four TB agents likely to be effective, and that at least three agents are included for the rest of treatment after bedaquiline is stopped. If only one or two Group A agents are used, both Group B agents are to be included. If the regimen cannot be composed with agents from Groups A and B alone, Group C agents are added to complete it (Group A: fluoroquinolones (levofloxacin and moxifloxacin), bedaquiline and linezolid were considered highly effective and strongly recommended for inclusion in all regimens unless contraindicated.– Group B: clofazimine and cycloserine or terizidone were conditionally recommended as agents of second choice.– Group C: included all other medicines that can be used when a regimen cannot be composed with Group A and B agents. The medicines in Group C are ranked by the relative balance of benefit to harm usually expected of each)
Also Featured In
This recommendation also appears in the following guidelines:
WHO consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-resistant tuberculosis treatment
WHO consolidated guidelines on tuberculosis: Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update
WHO consolidated guidelines on tuberculosis: module 4: treatment and care